Skip to main content
Article thumbnail
Location of Repository

Common Gene Variants in the Tumor Necrosis Factor (TNF) and TNF Receptor Superfamilies and NF-kB Transcription Factors and Non-Hodgkin Lymphoma Risk

By Sophia S. Wang, Mark P. Purdue, James R. Cerhan, Tongzhang Zheng, Idan Menashe, Bruce K. Armstrong, Qing Lan, Patricia Hartge, Anne Kricker, Yawei Zhang, Lindsay M. Morton, Claire M. Vajdic, Theodore R. Holford, Richard K. Severson, Andrew Grulich, Brian P. Leaderer, Scott Davis, Wendy Cozen, Meredith Yeager, Stephen J. Chanock, Nilanjan Chatterjee and Nathaniel Rothman
Topics: Research Article
Publisher: Public Library of Science
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2008). A functional TNFRSF5 gene variant is associated with risk of lymphoma.
  2. (2008). A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia.
  3. (2007). A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma.
  4. (2006). A tail strength measure for assessing the overall univariate significance in a dataset.
  5. (2007). Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications.
  6. (2008). Atacicept (TACI-Ig) inhibits growth of TACI(high) primary myeloma cells in SCID-hu mice and in coculture with osteoclasts.
  7. (2004). Cancer: an inflammatory link.
  8. (2006). Causes and consequences of the autoimmune lymphoproliferative syndrome.
  9. (2001). Collection of genomic DNA from adults in epidemiological studies by buccal cytobrush and mouthwash.
  10. (2006). Common genetic variants in proinflammatory and other immunoregulatory genes and risk for non-Hodgkin lymphoma.
  11. (2001). Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells.
  12. (1995). Controlling the false discovery rate: a practical and powerful approach to multiple testing.
  13. (2006). Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma.
  14. (2000). Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.
  15. (2006). Elevated serum B-lymphocyte stimulator levels in patients with familial lymphoproliferative disorders.
  16. (2000). Expression of interferon regulatory factor 4 in chronic myeloid leukemia: correlation with response to interferon alfa therapy.
  17. (2007). Fas (CD95) induces macrophage proinflammatory chemokine production via a MyD88-dependent, caspase-independent pathway.
  18. (2003). Gene expression profiling of diffuse large B-cell lymphoma. Leuk Lymphoma.
  19. (2005). Genetic variation and willingness to participate in epidemiologic research: data from three studies.
  20. (2007). Genetic variation in 1253 immune and inflammation genes and risk of nonHodgkin lymphoma.
  21. (2006). Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium.
  22. (2008). Genetic variation in tumor necrosis factor and the nuclear factor-kappaB canonical pathway and risk of non-Hodgkin’s lymphoma.
  23. (2004). Haircoloring product use and risk of non-Hodgkin’s lymphoma: a population-based case-control study in Connecticut.
  24. (2005). Haploview: analysis and visualization of LD and haplotype maps.
  25. (2003). Identification of I kappa BL as the second major histocompatibility complexlinked susceptibility locus for rheumatoid arthritis.
  26. (1997). Immunoregulatory genes and immunosuppression by glucocorticoids. Arch Toxicol Suppl:
  27. (1995). Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis.
  28. (2000). Inhibition of NF-kappaB induces apoptosis of KSHV-infected primary effusion lymphoma cells.
  29. (2008). IRF4 addiction in multiple myeloma.
  30. (2004). Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL.
  31. (2005). MALT1 and the API2-MALT1 fusion act between CD40 and IKK and confer NF-kappa Bdependent proliferative advantage and resistance against FAS-induced cell death in B cells.
  32. (2003). Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma.
  33. (2002). Multiple tests for genetic effects in association studies. Methods Mol Biol.
  34. (2007). New transcription factors in diagnostic hematopathology.
  35. (2004). NF-kappaB functions as a tumour promoter in inflammation-associated cancer.
  36. (2001). Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues.
  37. (1995). Phosphorylation of I kappa B alpha precedes but is not sufficient for its dissociation from NF-kappa B.
  38. (2004). Pigmentary characteristics, sun sensitivity and non-Hodgkin lymphoma.
  39. (2007). Polymorphisms in immune function genes and risk of non-Hodgkin lymphoma: findings from the New South Wales non-Hodgkin Lymphoma Study.
  40. (2007). Proposed classification of lymphoid neoplasms for epidemiologic research from the International Lymphoma Epidemiology Consortium (InterLymph).
  41. Radbruch A (2006) IRF4 - a factor for class switching and antibody secretion.
  42. (2006). Resampling-based multiple hypothesis testing procedures for genetic case-control association studies.
  43. (2004). Risk of nonHodgkin’s lymphoma and family history of lymphatic, hematologic, and other cancers.
  44. (2004). Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium.
  45. (2006). SNP500Cancer: a public resource for sequence validation, assay development, and frequency analysis for genetic variation in candidate genes.
  46. Tangye SG (2004) The role of the BAFF/APRIL system in B cell homeostasis and lymphoid cancers.
  47. (2007). The BCL6 proto-oncogene: a leading role during germinal center development and lymphomagenesis.
  48. (2007). The endless complexity of lymphocyte differentiation and lymphomagenesis: IRF-4 downregulates BCL6 expression.
  49. (2007). The rGel/BLyS fusion toxin specifically targets malignant B cells expressing the BLyS receptors BAFF-R, TACI, and BCMA.
  50. (2007). The role of death receptor ligands in shaping tumor microenvironment.
  51. (2006). Travelling with the BAFF/BLyS family: are we there yet?

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.